Rocket Pharmaceuticals, Inc. (RCKT) Revenue, Earnings & Financial Statements
$2.11NASDAQ: RCKTMarket Cap $235.60M
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Rocket Pharmaceuticals, Inc. most recently reported annual revenue of $0, a net loss of $223.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Rocket Pharmaceuticals, Inc.: net profit was positive in 0 of 10 reported years; the most recent year shows a net loss of $223.0M.
Income Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$42.0M
$27.0M
$71.0M
$76.0M
$136.0M
$167.0M
$224.0M
$260.0M
$273.0M
$229.0M
Operating Profit
−$42.0M
−$27.0M
−$71.0M
−$76.0M
−$136.0M
−$167.0M
−$224.0M
−$260.0M
−$273.0M
−$229.0M
Other Income
−$1.0M
−$3.0M
−$3.0M
−$1.0M
−$4.0M
−$2.0M
$2.0M
$14.0M
$14.0M
$5.0M
Interest
$1.0M
$4.0M
$5.0M
$5.0M
$8.0M
$6.0M
$2.0M
$2.0M
$2.0M
$2.0M
Depreciation
$0
$0
$0
$0
$1.0M
$5.0M
$6.0M
$7.0M
$9.0M
$11.0M
Profit Before Tax
−$43.0M
−$29.0M
−$75.0M
−$77.0M
−$140.0M
−$169.0M
−$222.0M
−$246.0M
−$259.0M
−$223.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
-5.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$43.0M
−$29.0M
−$75.0M
−$83.0M
−$147.0M
−$169.0M
−$222.0M
−$246.0M
−$259.0M
−$223.0M
EPS
−$6.41
−$4.36
−$1.89
−$1.70
−$2.52
−$2.68
−$3.26
−$2.92
−$2.73
−$2.01
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$63.0M
$67.0M
$74.0M
$69.0M
$63.0M
$64.0M
$71.0M
$52.0M
$44.0M
$49.0M
$47.0M
$51.0M
Operating Profit
−$63.0M
−$67.0M
−$74.0M
−$69.0M
−$63.0M
−$64.0M
−$71.0M
−$52.0M
−$44.0M
−$49.0M
−$47.0M
−$51.0M
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$3.0M
$0
$0
$0
Profit Before Tax
−$60.0M
−$62.0M
−$70.0M
−$67.0M
−$60.0M
−$61.0M
−$69.0M
−$50.0M
−$43.0M
−$48.0M
$132.0M
−$49.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
6.5%
-0.1%
Net Profit
−$60.0M
−$62.0M
−$70.0M
−$67.0M
−$60.0M
−$61.0M
−$69.0M
−$50.0M
−$43.0M
−$48.0M
$123.0M
−$49.0M
EPS
−$0.64
−$0.66
−$0.74
−$0.71
−$0.62
−$0.56
−$0.62
−$0.45
−$0.38
−$0.42
$1.08
−$0.43
Over the 10 years reported for Rocket Pharmaceuticals, Inc., borrowings decreased from $49.0M in 2016 to $25.0M in 2025, cash stood at $78.0M in the latest year, shareholders' equity was $1.0M, current assets covered current liabilities 6.43 times.
Balance Sheet — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$130.0M
$102.0M
$251.0M
$372.0M
$591.0M
$497.0M
$552.0M
$566.0M
$528.0M
$330.0M
Current Assets
$128.0M
$101.0M
$209.0M
$308.0M
$487.0M
$392.0M
$364.0M
$378.0M
$378.0M
$193.0M
Cash
$30.0M
$79.0M
$111.0M
$185.0M
$297.0M
$233.0M
$141.0M
$56.0M
$164.0M
$78.0M
Inventory
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Receivables
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Fixed Assets
$1.0M
$1.0M
$2.0M
$31.0M
$71.0M
$72.0M
$78.0M
$88.0M
$83.0M
$72.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$97.0M
$22.0M
$102.0M
$120.0M
$186.0M
$156.0M
$259.0M
$352.0M
$209.0M
$113.0M
Other Assets
$0
$0
$31.0M
$31.0M
$31.0M
$31.0M
$39.0M
$39.0M
$39.0M
$39.0M
Total Liabilities
$56.0M
$54.0M
$57.0M
$65.0M
$87.0M
$42.0M
$62.0M
$74.0M
$64.0M
$53.0M
Current Liabilities
$7.0M
$4.0M
$15.0M
$18.0M
$33.0M
$22.0M
$39.0M
$49.0M
$41.0M
$30.0M
Borrowings
$49.0M
$50.0M
$41.0M
$47.0M
$62.0M
$23.0M
$23.0M
$25.0M
$25.0M
$25.0M
Other Liabilities
$8.0M
$4.0M
$16.0M
$17.0M
$26.0M
$20.0M
$39.0M
$49.0M
$39.0M
$28.0M
Equity
$0
$0
$0
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
Reserves
$73.0M
$48.0M
$194.0M
$307.0M
$504.0M
$455.0M
$490.0M
$493.0M
$463.0M
$277.0M
For Rocket Pharmaceuticals, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $190.0M; free cash flow was positive in 0 of 10 years.
Cash Flow Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
−$37.0M
−$26.0M
−$54.0M
−$65.0M
−$75.0M
−$121.0M
−$178.0M
−$195.0M
−$210.0M
−$190.0M
Investing Cash Flow
−$67.0M
$75.0M
−$7.0M
−$62.0M
−$126.0M
$11.0M
−$78.0M
−$115.0M
$126.0M
$103.0M
Financing Cash Flow
$0
$0
−$1.0M
$0
−$4.0M
$0
$0
$0
$0
$0
Net Cash Flow
−$50.0M
$49.0M
$94.0M
$74.0M
$112.0M
−$65.0M
−$92.0M
−$85.0M
$108.0M
−$86.0M
Free Cash Flow
−$38.0M
−$26.0M
−$55.0M
−$88.0M
−$104.0M
−$129.0M
−$187.0M
−$211.0M
−$216.0M
−$190.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
-0.11
EV / EBITDA
36.90
FCF Yield
-63.07%
Quick Ratio
7.25
Interest Coverage
-40.26
Return 1Y
-28.45%
Return 3Y
-90.09%
Return 5Y
-91.96%
Rocket Pharmaceuticals, Inc. (RCKT) financials — frequently asked questions
What is Rocket Pharmaceuticals, Inc.'s annual revenue?
Rocket Pharmaceuticals, Inc. (RCKT) reported annual revenue of $0 in its most recent fiscal year.
What is Rocket Pharmaceuticals, Inc.'s net profit?
Rocket Pharmaceuticals, Inc. (RCKT) reported a net loss of $223.0M in its most recent fiscal year.
What is RCKT EV/EBITDA?
Rocket Pharmaceuticals, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 36.90.
Revenue and earnings of other Biotechnology stocks